ArticleBMC neurology2026
Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study was designed to investigate the association of IL-18-137G/C (rs187238) and IL-21-1472G/T (rs2055979) single nucleotide polymorphisms (SNPs) with the risk of MS, the disease progression, and related clinical features.
methodsIn this study, 271 Egyptian individuals participated, including 131 MS cases (relapsing-remitting (RR-MS) cases [N = 99], and progressive MS cases [N = 32]) and 140 unrelated healthy controls. The association between IL-18-137G/C (rs187238) and IL-21-1472G/T (rs2055979) single nucleotide polymorphisms (SNPs) and the risk of MS and the disease progression, as well as the clinical features including the disability progression and the severity, were analyzed by using polymerase chain reaction (PCR) methods.
resultsThe GC genotype and C allele of the IL-18 SNP were linked to susceptibility to MS, and the genotypic forms (GC and CC genotypes) and allelic form (C allele) were linked to an elevated risk of the development of progressive MS. Regression investigation further strengthened the notion that this SNP is a predictor of the disability of the disease according to the Disability Status Scale (EDSS) values. For the IL-21-1472G/T SNP, the TT genotype and T allele in the Egyptian cohort were related to the reduced risk of progressive MS when comparing the two diseased forms; however, they were not associated with the disability progression and severity of the disease.
conclusionThe IL-18-137G/C SNP might be a possible risk determinant of the susceptibility as well as the progression of MS. In contrast, the IL-21-1472G/T SNP could protect against progressive MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.